rotigotine

CLINICAL USE

Treatment of Parkinson’s disease

DOSE IN NORMAL RENAL FUNCTION

2–8 mg every 24 hours With levodopa: max 16 mg every 24 hours

PHARMACOKINETICS

Molecular weight :315.5

%Protein binding :92

%Excreted unchanged in urine : 71

Volume of distribution (L/kg) :84

half-life – normal/ESRD (hrs) :5–7/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antipsychotics: avoid concomitant use (antagonism of effect)Metoclopramide: avoid concomitant use (antagonism of effect)

ADMINISTRATION

Reconstition

–

Route

Topical

Rate of Administration

–

Comments

–

OTHER INFORMATION

Discontinue gradually at a rate of 2 mg/24 hours, every other day
Apply to intact skin on the abdomen, thigh, hip, flank, shoulder or upper armIf a patch falls off replace with a new one Backing layer contains aluminium and should be removed prior to MRIs or cardioversionRotigotine is being investigated for its use in restless legs syndrome.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home